Anti‐human interleukin‐6 receptor antibody inhibits human myeloma growth in vivo

European Journal of Immunology - Tập 22 Số 8 - Trang 1989-1993 - 1992
Hiroshi Suzuki1, Kiyoshi Yasukawa2, Takashi Saito2, Ryo Goitsuka3, Atsuhiko Hasegawa3, Yoshiyuki Ohsugi4, Tetsuya Taga5, Tadamitsu Kishimoto6
1Biotechnology Research Laboratory, Tosoh Corporation, Kanagawa, Japan
2Biotechnology Research Laboratory, Tosoh Corporation, Kanagawa.
3Department of Veterinary Internal Medicine, Faculty of Agriculture, University of Tokyo, Tokyo
4Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Shizuoka
5Institute for Molecular and Cellular Biology, Osaka University, Osaka
6Department of Medicine III, Osaka University Medical School, Osaka

Tóm tắt

AbstractMyeloma is one of the interleukin (IL)‐6‐related diseases to which abnormal expression of IL‐6 has been reported to be linked. We examined the in vivo inhibitory effect of anti‐human IL‐6 receptor (IL‐6R) antibody on human myeloma cell growth in mice. SCID mice were subcutaneously inoculated with solid tumor of the myeloma cell line S6B45 in which human IL‐6 was acting as an autocrine growth factor. Ten intraperitoneal administrations of 100 μg of the anti‐human IL‐6R antibody PM1 at 48‐h intervals strongly inhibited the growth of S6B45 cells when the administration started 24 h after tumor inoculation. The tumor growth inhibition in vivo was also observed by administration of the anti‐human IL‐6 antibody MH166 using the same procedure as for PM1. The inhibitory effect of PM1 was not significant when the administration started 5 or more days after tumor inoculation. This work indicates that anti‐human IL‐6R antibody, as well as anti‐human IL‐6 antibody inhibits human myeloma growth in vivo, and provides an animal model for testing the therapeutic value of agents such as antibodies to human IL‐6, IL‐6R and gp130, an IL‐6R‐associated signal transducer, in the treatment of human myelomas.

Từ khóa


Tài liệu tham khảo

10.1016/0167-5699(90)90173-7

10.1073/pnas.84.1.228

10.1002/eji.1830181122

10.1073/pnas.87.11.4068

10.1084/jem.172.5.1505

Yoshizaki K., 1989, Blood, 74, 1360, 10.1182/blood.V74.4.1360.1360

10.1038/332083a0

10.1182/blood.V72.5.1826.1826

10.4049/jimmunol.143.12.3949

Klein B., 1990, Eur. Cytokine Net., 1, 193

10.1182/blood.V78.5.1198.1198

10.4049/jimmunol.143.9.2900

Saito T., 1991, J. Immunol., 147, 168, 10.4049/jimmunol.147.1.168

10.1016/0165-2478(91)90083-M

10.1084/jem.172.3.997

10.1038/301527a0

10.1126/science.2595371

10.1002/eji.1830180618

10.1016/0092-8674(90)90411-7

Okuno Y. Takahashi T. Ichiba S. Nakamura K. Fukumoto M. Okada T. Okada H.andImura H. Exp. Hematol.1992 in press.

Okuno Y., 1991, Leukemia, 5, 585

10.1016/0022-1759(86)90368-6

10.1084/jem.171.2.389

10.1182/blood.V73.2.517.517

10.1016/0092-8674(89)90438-8

10.1093/oxfordjournals.jbchem.a123261

Tonouchi N., 1989, J. Biochem., 104, 30, 10.1093/oxfordjournals.jbchem.a122416

10.1007/BF01024396

10.1016/0165-2478(92)90138-E

Thông tin
Thông tin xuất bản

European Journal of Immunology

Tập 22 Số 8

1989-1993

Thông tin tác giả